Medtech company MedAlliance raises over USD 50 million to commercialize drug-eluting balloons

 

Vaud-based MedAlliance has raised over USD 50 Million in equity funding for its novel balloon that provides a controlled sustained release of a limus drug. This financing will be used to fund the commercialization of SELUTION SLR and support global clinical programs.

 

MedAlliance’s SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of a limus drug, with a similar elution time to that of a drug-eluting stent (DES), whilst leaving nothing behind.

Dedicated to developing innovative drug-eluting balloons (DEBs) for patients suffering from life-threating coronary and peripheral arterial disease, the company uses breakthrough proprietary technology that combines the proven safety and efficacy of the cytostatic drug sirolimus with microreservoirs made of biodegradable polymer as drug delivery systems and with a proprietary lipid technology which binds the microreservoirs to the balloon surface.

The fundraising of over USD 50 million was made possible thanks to new investor Trustar Capital, a private equity affiliate of China’s CITIC Capital Holdings Limited.

“We are very pleased to have Trustar Capital as a valued partner and have established a strong relationship with their team over a substantial period of time. Their in-depth knowledge and expertise in the global medical device market will be of tremendous benefit to us”, says Jeffrey B. Jump, Chairman and CEO of MedAlliance.

Headquartered in Nyon (canton of Vaud), in the heart of the “Health Valley”, MedAlliance is the first drug-eluting balloon company in the world to receive US FDA Breakthrough Device Designation Status for a sirolimus DEB, which has recently been awarded breakthrough status for SELUTION SLR in the treatment of atherosclerotic lesions in native coronary arteries.

HubsGoGlobal is a platform under the PharmaBoardroom brand that focuses on the competitive advantages of the Hub and its value proposition in terms of strategic, operational, financial, talent and lifestyle aspects.

PharmaBoardroom provides industry trends, news and reports from all over the world. This site is for senior professionals who want to understand local and global markets.

CONTACT

Greater Geneva Bern area is an initiative of the cantons of
Bern, Fribourg, Vaud, Neuchâtel, Geneva and Valais.

World Trade Center – Av. de Gratta-Paille 2
PO Box 252
1000 Lausanne 22 – Switzerland

CONTACT

Copyright: All rights reserved. No part of this site maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this website, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

2021 © PharmaBoardroom